Skip to main content

Table 6 Patient’s reported outcome measures and healthcare outcomes/quality of life

From: Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review

Patient’s reported outcome measures and

healthcare outcomes/quality of life

Number of studies present (%)

Headache Impact Test (HIT-6)

32 (69.6%) [39, 41,42,43,44, 46,47,48,49, 53, 55,56,57,58,59, 61, 62, 65,66,67,68,69, 72, 74,75,76, 78,79,80,81,82,83]

Migraine Disability Assessment questionnaire (MIDAS)

22 (47.8%) [38, 44, 46,47,48, 51,52,53, 57,58,59, 61, 67, 72,73,74, 76, 78,79,80,81, 83]

Migraine-Specific Quality of Life questionnaire (MSQ v2.1)

7 (15.2%) [38, 45, 53, 72, 74, 76, 77]

Patient Global Impression of Change (PGIC)

6 (13%) [38, 45, 46, 55, 58, 76]

Allodynia Symptom Checklist (ASC-12)

4 (8.7%) [48, 53, 72, 74]

EuroQoL-5 Dimension Questionnaire (EQ-5D)

1 (2.2%) [75]

Short Form 12-Item Health Survey (SF12)

1 (2.2%) [75]

Functional Impairment Scale (FIS)

0

Migraine Functional Impact Questionnaire (MFIQ)

0